ABSTRACT
INTRODUCTION
Pre-eclampsia is one of the most dangerous health problems of human pregnancy. It is diagnosed by the new appearance of hypertension and proteinuria after 20 weeks gestation. It is a leading cause of fetal growth restriction, premature birth, and low birth weight babies (1) . Preeclampsia complicates 5-7% of all pregnancies. Preeclampsia occurs with increased frequency among young, nulliparous women.
However, the frequency distribution is bimodal, with a second peak occurring in multiparous women greater than 35 years of age. Among daughters of preeclamptic women, the risk of preeclampsia is significantly higher than the population risk (1) . Preeclampsia is a hypertensive disorder of pregnancy characterized by increased vasoconstriction leading to maternal hypertension and reduced blood flow to organs and tissues, including the kidney, uterus and placenta.
Increased platelet aggregation, disseminated intravascular coagulation, endothelial cell dysfunction, proteinuria and edema are other abnormalities associated with preeclampsia. Severe preeclampsia can lead to eclampsia,which is characterized by maternal convulsions thought to be caused by cerebral vasoconstriction. Despite of considerable research on preeclampsia,the only treatment present is removal of the fetus and placenta (2) . During uncomplicated pregnancy, there is an increased production of pro-oxidant that is balanced by the synthesis of antioxidant. In preeclampsia, there is an imbalance between pro-oxidant and antioxidant defenses. It is uncertain whether an imbalance between pro-oxidants and antioxidants (oxidative stress) precedes preeclampsia or occurs after preeclampsia has developed. Oxidative stress can cause cellular dysfunction, growth arrest or ultimately cell death (3) . Activin A is a glycoprotein hormone produced by many tissues. During normal pregnancy the fetoplacental unit is the main source of activin A, with the placenta producing the majority of secreted activin A. It belongs to Transforming Growth Factor β (TGFβ) superfamily. TGFβ superfamily is a group of proteins whose members are involved in control of cell proliferation and differentiation in many systems (4) . Maternal serum levels of activin A increase from about mid-pregnancy to a peak close to term (5) , falling quickly after birth (6) . In pregnancies complicated by placental dysfunction as evidenced by intrauterine fetal growth restriction (7) , or preeclampsia (8,9) maternal serum levels of activin A are significantly higher than observed in normal pregnancy.
The adaptive trophoblast proliferation in pre-eclampic placenta may be the major source of activin A. However, since activin A is a growth factor affecting cell proliferation in various tissues, the trophoblast proliferation in preeclampsia may be secondary to the increased production of activin A. The mechanism underlying such increased placental output remains unclear (10) . The aim of the present study is to evaluate the levels of activin A and malondialdehyde (MDA) in pregnancy hypertensive states and to explore whether circulating levels of activin A are correlated to MDA levels (marker of oxidative stress) .
SUBJECTS & METHODS
The present study was carried out at Beni Suef University, Maternity hospital. In this study 75 pregnant women were included, their age ranged from 18 to 35 years and gestational age of (26-40) weeks. They were divided into three groups: GroupI (n=25): pregnant women with  normal  blood  pressures,  no  proteinuria,  and  no Table ( 2): Comparative study regarding clinical and biochemical parameters between normal, PIH and preeclampsia groups. There was a highly significant difference (p<0.001) in SBP and DBP in"PIH" and preeclampsia groups when compared to control group. Also, there was a highly significant difference (p<0.001) in SBP and a significant difference (p<0.05) in DBP of "PIH" group when compared to pre-eclamptic group.There was no significant difference (p>0.05) in serum AST,ALT,platelet count, urinary creatinine, P.T and INR levels between normal & "PIH" groups ,but there was a significant difference (p<0.05) in serum AST, ALT, urinary creatinine, P.T, and INR levels between control & preeclampsia groups. In addition there was a significant difference (p<0.05) between "PIH" & pre-eclampsia groups as regard the previous markers. Concerning proteinuria, a highly significant difference (p<0.001) was found between "PIH" (nil) & pre-eclamptic groups. Table ( 3), figure (1) and figure (2): Showing a comparative study regarding serum levels of activin A and MDA between all studied groups. There was a highly significant difference (p<0.001) in serum activin A and MDA levels in"PIH" and pre-eclamptic groups when compared to control group. Also, there was a highly significant difference (p<0.001) in serum activin A and MDA levels between PIH and pre-eclamptic groups. 
DISCUSSION
Pre-eclampsia is a human pregnancy specific disorder that is diagnosed by the new onset of hypertension and proteinuria after 20 weeks gestation. It is a leading cause of perinatal morbidity and mortality and the only intervension that reverses the syndrome is delivery
(1) . Oxidative stress of placenta is considered to be a key intermediary step in the pathogenesis of pre-eclampsia,but the cause of stress remains unknown.Hypoxiareoxygenation (H/R) injury, as a result of intermittent placental perfusion secondary to deficient trophoplast invasion of the endometrial arteries is a possible mechanism (14) . Activin A is a glycoprotein hormone produced by many tissues .During the normal pregnancy the fetoplacental unit is the main source of activin A, with the placenta producing the majority of secreted activin A. It belongs to TGFβ superfamily, a group of proteins whose members are involved in control of cell proliferation and differentiation in many systems (4) . Accordingly, this study was undertaken to explore whether oxidative stress may be the mechanism underlying increased placental activin A production in preeclampsia and to explore whether circulating levels of activin were correlated with circulating levels of a marker of systemic oxidative stress.
In the present study,serum levels of activin A were significantly higher (p< 0.001) in pre-eclampsia group than "PIH" group compared to control .These results are supported by Mandang et al. (15) who reported that circulating levels of activin A are significantly increased in women with pre-eclampsia, gestational age 26-40 weeks, when compared with those with a normal pregnancy .
Spencer et al. (16) studied the use of measurement of serum activin A level in the 1 st trimester in prediction of pre-eclampsia. They concluded that although activin A is increased in the first trimester, levels of activin-A is probably too low to make a significant contribution to screening for preeclampsia at this time.
Aparna Reddy et al. (17) reported that, the levels of activin A in preeclamptic women were significantly higher in pre-delivery samples compared to normal pregnant women. With placental separation, the levels of circulating activin A declined rapidly and dropped significantly after 24 hours in normal pregnancy and in pre-eclampsia, suggesting the placenta is the major source of increased levels of activin A in pre-eclamptic women.
Yu et al. (18) concluded that in early second-trimester serum inhibin A, activin A, placental growth factor (PlGF) and second-trimester uterine artery Doppler may add further information for the prediction of preeclampsia. The combination of the three serum markers and uterine artery Doppler has the highest prediction value for pre-eclampsia.
The present results clearly show high concentrations of activin A in the maternal circulation of pregnant women with pre-eclampsia. The increased serum activin A level is due to decreased urinary clearance, increased placental production, or a combination of these factors. The evidence that patients with pregnancy-induced hypertension had lower activin A plasma concentration than pre-eclamptic patients suggests that the high concentrations of activin A are not correlated with the high blood pressure but with the entity of gestational disease.. These findings also suggest that it's not the hypertensive state that induces the release of activin A, but the placental or fetal changes associated with the disease.It was reported that the putative source of activin A in maternal circulation is placenta, even though a contribution of maternal decidua cannot be ruled out (19) . On the contrary, Khalil et al.
(20)
studied the effect of the use of the anti hypertensive α-methyl dopa, on serum activin A level in 65 women with preeclampsia and concluded that antihypertensive therapy with alphamethyl dopa may have an effect on the synthesis and/or release of placental activin A in pregnancies complicated by preeclampsia . In pre-eclamptic patients the proliferation of trophoblast has been proposed to explain the increased concentrations of several placental hormones in maternal circulation (21) . The adaptive trophoblast proliferation in pre-eclamptic placenta may be the major source of activin A. However, since activin A is a growth factor affecting cell proliferation in various tissues (10) , the trophoblast proliferation in preeclampsia may be secondary to the increased production of activin A.
Recently, molecular evidence of placental hypoxia in pre-eclampsia feto-placental hypoxia increase amniotic fluid levels of activin A. Hypoxia has been explored as a possible cause of increased placental activin A production in vivo (19) . However, in contrast to the in vivo ovine data, in vitro culture of first trimester and term human placental explants under low oxygen conditions consistently reduced activin A production (25) , suggesting that placental hypoxia is not a likely cause of the increased activin A observed in preeclampsia.
Also, in the present study, the circulating activin A was significantly and positively correlated with systolic and diastolic blood pressure. These results could be explained by the experimental evidence indicating that activin A modulates endothelin secretion by vascular endothelial cells and that activin-like immunoreactivity is present in vascular endothelial cells (26) , suggesting a possible autocrine role of activin A on hypertension . Another organ involved in the regulation of blood pressure which produces and may be a target of activin is the kidney. In fact, recent findings have shown that TGF-ß mediates the angiotensin II-induced hypertrophy of proximal tubular cells in cultured murine kidney cells (27) . Also, in the present study, higher levels of MDA were found in both patients with preeclampsia and pregnancy induced hypertension than that of normal pregnancy group. There was further increase in MDA levels in preeclamptic group of patient than its levels in PIH group. These findings were supported by Adiga et al.
(3) that reported, in preeclampstic women, lipidperoxidation products especially malondialdehyde (MDA) increase. Increased placental oxidative stress has been linked to the systemic features of preeclampsia through the release of a variety of possible mediators of endothelial cell dysfunction such as lipid peroxides, pro-inflammatory cytokines (28,29) and syncytiotrophoblast microparticles (30) . Cytokines as tumour necrosis factor α (TNF-α) and interleukins, may contribute to the oxidative stress associated with preeclampsia. In this case, oxygen-free radicals lead to the formation of self propagating lipid peroxides (31) . Lipid peroxides are directly involved in mediating maternal endothelial dysfunction by increasing the production of thromboxane A2 and the expression of cell adhesion molecules in the utero-placental vasculature and also in the maternal peripheral vasculature (32) .
Howlader et al.
(33) observed that thiobarbituric acid reactive substances (TBARS), lipid hydroperoxide and protein carbonyl content were significantly increased but total antioxidant status and vitamin C level were significantly decreased in cord blood from pre-eclamptic mother compared to control group, suggesting that pre-eclampsia is associated with increased oxidative stress and decreased anti-oxidant status.
Also,in the present study, the circulating levels of activin A were significantly and positively correlated with MDA increased in women with preeclampsia and PIH when compared with those in a normal pregnancy. These results are consistent with Mandang et al. (15) who found that maternal plasma levels of F8-isoprostane and activin A were significantly higher in women with preeclampsia when compared with controls. These data suggest that oxidative stress may be one of the mechanisms underlying increased circulating activin A in preeclampsia. The results could be explained by the work of Michael Cackovic et al. (34) who reported that women with preeclampsia have higher levels of TNF-α compared with normal pregnant women and elevated levels of TNF-α protein and mRNA have also been demonstrated in their placentas. TNF-α can activate the endothelial cells and upregulate the gene expression of numerous molecules such as platelet derived growth factor, cell adhesion molecules, endothelin-1 and PAI-1.These molecules have been reported to have detriminental effects on the vasculature and also characterize preeclamptic pregnancy. Furthermore, chronic infusion of TNF-α into rats during late pregnancy results in significant increase in renal vascular resistance and arterial pressure (35) . In conclusion, our study confirmed that the serum levels of activin A and MDA were elevated in preeclampia and PIH compared to normal pregnancy and this elevation is more obvious in preeclampsia than PIH indicating that activin A was involved in pathogenesis and severity of preeclampsia. Also, increased MDA levels, revealing an increase in lipidic membrane damage in preeclamptic patients as compared with healthy pregnant patients. Activin A and MDA levels in serum are positively correlated in PIH and preeclampsia groups suggesting that oxidative stress may play a role in activin A production. 
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